Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
Pivotal Trial
Summary
This trial tests a drug to treat ulcerative colitis, in people who haven't responded to other treatments.
Who is the study for?
This trial is for men and women at least 16 years old with moderate to severe ulcerative colitis who haven't responded well or are intolerant to certain therapies like corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors. Participants must have a confirmed diagnosis of UC for over 90 days and active disease. They should agree to use effective contraception if applicable.
What is being tested?
ABTECT-1 is testing the effectiveness and safety of ABX464 in doses of either 25 mg or 50 mg daily compared to a placebo in achieving clinical remission in patients with ulcerative colitis. The study randomly assigns participants to receive either ABX464 or a placebo alongside their standard treatments.
What are the potential side effects?
While specific side effects for ABX464 aren't listed here, common side effects from drugs treating ulcerative colitis may include headache, nausea, fatigue, abdominal pain, and potential increased risk of infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8
Secondary study objectives
Proportion of subjects who achieve clinical response per MMS at week 8
Proportion of subjects who achieve endoscopic improvement at week 8
Proportion of subjects with HEMI per Geboes at week 8
+1 moreSide effects data
From 2019 Phase 2 trial • 32 Patients • NCT0309325917%
Abdominal pain
17%
Headache
13%
Abdominal pain upper
9%
Chest pain
9%
Influenza like illness
9%
Nausea
4%
Peripheral vascular disorder
4%
Dyspnoea
4%
Dyspepsia
4%
Haematoma
4%
Oropharyngeal pain
4%
Alopecia
4%
Rhinitis
4%
Hypophosphataemia
4%
Anorectal discomfort
4%
Nasopharyngitis
4%
Oral herpes
4%
Anal fissure
4%
Influenza
4%
Sinusitis
4%
Upper respiratory tract infection
4%
Ligament sprain
4%
AST/ALT ratio
4%
Iron deficiency
4%
Back pain
4%
Poor quality sleep
4%
Skin discolouration
100%
80%
60%
40%
20%
0%
Study treatment Arm
ABX464
Placebo
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: ABX464 50mgExperimental Treatment1 Intervention
Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
Group II: ABX464 25mgExperimental Treatment1 Intervention
Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
Group III: PlaceboPlacebo Group1 Intervention
Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABX464
2021
Completed Phase 2
~310
Find a Location
Who is running the clinical trial?
Abivax S.A.Lead Sponsor
21 Previous Clinical Trials
3,835 Total Patients Enrolled
6 Trials studying Colitis
1,778 Patients Enrolled for Colitis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently taking medication for diarrhea.I have primary sclerosing cholangitis or autoimmune hepatitis.My ulcerative colitis affects only the very end of my colon.I have had severe colon issues, like toxic megacolon or a perforated bowel.I have been cancer-free for 5 years.I have not responded well to treatments like steroids, immunosuppressants, or biologics.I have been treated with ABX464 before.I have tried 5-ASA therapy without success.I have a history of torsade de pointes.I have a history of colon cancer or untreated polyps.I am currently taking probiotics such as Culturelle or Saccharomyces boulardii.I haven't had a live vaccine in the last 3 months and won't get one during the study.I have read, understood, and signed the consent form for this study.I was diagnosed with ulcerative colitis over 3 months ago, confirmed by a scope and tissue test.I am using or willing to use effective birth control methods.My condition is active with a score of 5 or more, including bleeding and significant endoscopy findings.I have had or will have surgery on my intestines, or I currently have a stoma.I do not have severe heart failure or uncontrolled heart disease.I am at least 16 years old, weigh over 40 kg, and have fully developed physically.I have Crohn's disease or a history of certain types of colitis.I haven't been hospitalized for a serious illness in the last 4 weeks, UC flare excluded.I do not have a history of long QT syndrome nor an abnormal QT interval.I don't have major ongoing health issues affecting my lungs, liver, pancreas, kidneys, brain, or nerves.I have not had severe infections or active hepatitis, HIV, or tuberculosis recently.
Research Study Groups:
This trial has the following groups:- Group 1: ABX464 25mg
- Group 2: ABX464 50mg
- Group 3: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger